News | Clinical Decision Support | June 27, 2016

SNMMI Appropriate Use Criteria Now Fulfill Federal Requirements

Providers will be able to consult SNMMI’s multidisciplinary, evidence-based criteria for nuclear medicine procedures to satisfy coming clinical decision support regulations

SNMMI, appropriate use criteria, AUC, PAMA, qualified provider-led entity, PLE

June 27, 2016 — The Society of Nuclear Medicine and Molecular Imaging (SNMMI) has been named a qualified provider-led entity (PLE) under the Medicare Appropriate Use Criteria program for advanced diagnostic imaging. This will allow referring physicians to use SNMMI’s appropriate use criteria (AUC) to fulfill the requirements of the 2014 Protecting Access to Medicare Act (PAMA).

PAMA requires referring physicians to consult appropriate use criteria developed by a PLE in order to ensure cost-effective and appropriate utilization of advanced diagnostic imaging services (ADIS). The legislation requires the delivery of these criteria via a clinical decision support tool, which referring physicians would need to utilize when ordering ADIS. The AUC requirements were originally due to launch by January 2017; however, the Centers for Medicare and Medicaid Services is now expected to publish more substantive information on the development of clinical decision support tools, which will delay the implementation deadline by at least a year.

SNMMI is developing a comprehensive library of multidisciplinary, evidence-based AUC for high-value nuclear medicine procedures. It is currently finishing development of AUC for bone scintigraphy in malignant disease, ventilation perfusion imaging in pulmonary embolism, hepatobiliary scintigraphy in abdominal pain and positron emission tomography (PET)/computed tomography (CT) in restaging of malignant diseases. Development of six additional AUC has been started, including prostate cancer imaging, myocardial perfusion imaging with PET, somatostatin imaging, infection imaging, nuclear medicine procedures for thyroid cancer and gastrointestinal transit.

For more information: www.snmmi.org

Related Content

After radiosurgery concurrent with nivolumab in 59-year-old patient with melanoma BM (patient 1; Supplemental Tables 3 and 5), F-18 FET PET at follow-up 12 weeks after treatment initiation (bottom row) shows significant decrease of metabolic activity (TBRmean, ?28%) compared with baseline (top row), although MRI changes were consistent with progression according to iRANO criteria. Reduction of metabolic activity was associated with stable clinical course over 10 mo. CE = contrast-enhanced. Image created by

After radiosurgery concurrent with nivolumab in 59-year-old patient with melanoma BM (patient 1; Supplemental Tables 3 and 5), F-18 FET PET at follow-up 12 weeks after treatment initiation (bottom row) shows significant decrease of metabolic activity (TBRmean, ?28%) compared with baseline (top row), although MRI changes were consistent with progression according to iRANO criteria. Reduction of metabolic activity was associated with stable clinical course over 10 mo. CE = contrast-enhanced. Image created by N. Galldiks et al., Research Center Juelich, Juelich, Germany.

News | PET Imaging | May 05, 2021
May 5, 2021 — For patients with brain metastases, amino acid ...
The emergence of #therapeutic #radiopharmaceuticals and its adoption in #cancer care provide one more weapon in combating cancer

Getty Images

Feature | Radiation Oncology | May 04, 2021 | By Vinay Shivaprasad
The term nuclear medicine is associated with the diag
Change Healthcare unveiled InterQual 2021, the latest edition of the company’s flagship clinical decision support solution.
News | Clinical Decision Support | April 22, 2021
April 22, 2021 — Change Healthcare unveiled...
olecular Targeting Technologies, Inc. (MTTI) announced the issuance of United States Patent # 10,953,113. The patent claims a quick (5 min), easy and quantitative conversion of commercially available 18F-deoxyglucose (18F-FDG) to 18F-Fluroglucaric acid (18F-FGA).

Getty Images

News | PET Imaging | April 19, 2021
April 19, 2021 — Molecular Targeting Technologies, Inc.
The inflamed joints of a #rheumatoid #arthritis patient are clearly visible in the #PET images with the novel 68Ga-DOTA-Siglec-9 #radiopharmaceutical. Image courtesy of Anne Roivainen

The inflamed joints of a rheumatoid arthritis patient are clearly visible in the PET images with the novel 68Ga-DOTA-Siglec-9 radiopharmaceutical. Image courtesy of Anne Roivainen

News | PET Imaging | April 19, 2021
April 19, 2021 — The preliminary...
#NorthStar Medical #Radioisotopes, LLC, a global innovator in the development, production and commercialization of #radiopharmaceuticals used for #medicalimaging and #therapeutic applications, announced a corporate update highlighting progress across its key programs during the past twelve months and upcoming milestones.

NorthStar Medical Radioisotopes, Beloit, Wisconsin campus (Photo: Business Wire)

News | Radiopharmaceuticals and Tracers | April 16, 2021
April 16, 2021 — ...
Elsevier’s STATdx, a leading radiology diagnostic decision support solution, now includes select Merit-Based Incentive Payment System (MIPS) Measures validated by MDinteractive
News | Clinical Decision Support | April 02, 2021
April 2, 2021 — Elsevier, a global leader in research publishing and information analytics, announced a partnership w
Shine executives are joined by the company’s construction managers and partners at its medical isotope production facility. The group was commemorating the facility’s achievement of weathertight status

Shine executives are joined by the company’s construction managers and partners at its medical isotope production facility. The group was commemorating the facility’s achievement of weathertight status. Image courtesy of Shine Medical Technologies

News | Radiopharmaceuticals and Tracers | March 26, 2021
March 26, 2021 — Shine Medical Technologies LLC announced that construction of the exterior structure of its first-of